We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+21.5%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.75B
AUM Growth
+$332M
Cap. Flow
-$28.9M
Cap. Flow %
-0.5%
Top 10 Hldgs %
51.71%
Holding
444
New
223
Increased
65
Reduced
45
Closed
77

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$54.6M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$40.8M
3
SGRY icon
Surgery Partners
SGRY
+$33.8M
4
LRMR icon
Larimar Therapeutics
LRMR
+$33.4M
5
ALHC icon
Alignment Healthcare
ALHC
+$30.6M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$62.6M
2
SWTX
SpringWorks Therapeutics
SWTX
+$60.2M
3
BAX icon
Baxter International
BAX
+$55M
4
VKTX icon
Viking Therapeutics
VKTX
+$36.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Industrials 0.71%
3 Technology 0.31%
4 Consumer Discretionary 0.26%
5 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RITM icon
301
Rithm Capital
RITM
$5.58B
$232K ﹤0.01%
+20,824
New +$224K
AVD icon
302
American Vanguard Corp
AVD
$68.7M
$232K ﹤0.01%
+17,931
New +$197K
EXPO icon
303
Exponent
EXPO
$3.19B
$229K ﹤0.01%
+2,774
New +$229K
FAST icon
304
Fastenal
FAST
$54.8B
$229K ﹤0.01%
+5,934
New +$210K
CUBI icon
305
Customers Bancorp
CUBI
$2.66B
$228K ﹤0.01%
4,297
-14
-0.3% -$737
SUPN icon
306
Supernus Pharmaceuticals
SUPN
$2.7B
$227K ﹤0.01%
6,654
-5,352
-45% -$159K
WWD icon
307
Woodward
WWD
$23B
$225K ﹤0.01%
1,463
-2,147
-59% -$302K
DYN icon
308
Dyne Therapeutics
DYN
$4.68B
$225K ﹤0.01%
+7,940
New +$180K
VCYT icon
309
Veracyte
VCYT
$4.45B
$222K ﹤0.01%
+10,011
New +$244K
LTC
310
LTC Properties
LTC
$2.13B
$222K ﹤0.01%
+6,818
New +$217K
HCC icon
311
Warrior Met Coal
HCC
$4.17B
$219K ﹤0.01%
+3,600
New +$218K
MET icon
312
MetLife
MET
$62.4B
$218K ﹤0.01%
+2,947
New +$205K
HROW icon
313
Harrow
HROW
$1.44B
$216K ﹤0.01%
+16,342
New +$174K
WINT
314
DELISTED
Windtree Therapeutics
WINT
$215K ﹤0.01%
+676
New +$258K
KTOS icon
315
Kratos Defense & Security Solutions
KTOS
$8.23B
$213K ﹤0.01%
+11,577
New +$211K
LAB icon
316
Standard BioTools
LAB
$342M
$212K ﹤0.01%
+78,090
New +$189K
S icon
317
SentinelOne
S
$6.35B
$210K ﹤0.01%
+9,023
New +$236K
KMX icon
318
CarMax
KMX
$8.39B
$210K ﹤0.01%
+2,407
New +$182K
ADPT icon
319
Adaptive Biotechnologies
ADPT
$3.61B
$210K ﹤0.01%
+65,287
New +$253K
SLRC icon
320
SLR Investment Corp
SLRC
$704M
$209K ﹤0.01%
+13,589
New +$206K
EXEL icon
321
Exelixis
EXEL
$13.9B
$208K ﹤0.01%
8,780
+380
+5% +$8.45K
LBPH
322
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$208K ﹤0.01%
+9,624
New +$210K
XRX icon
323
Xerox
XRX
$345M
$208K ﹤0.01%
+11,607
New +$204K
DHC
324
Diversified Healthcare Trust
DHC
$2.15B
$207K ﹤0.01%
+84,168
New +$241K
MSI icon
325
Motorola Solutions
MSI
$72.1B
$206K ﹤0.01%
580
-743
-56% -$245K
11 12
13
14 15

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2024 Portfolio in Review

As of Q1 2024, Deerfield Management held 444 positions worth $5.75B, up 6.1% from $5.42B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q1 2024 filing shows 223 new, 65 increased, 45 reduced and 77 closed positions. Its largest new stake was BioNTech: 569,574 shares worth $52.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 78% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q1 2024 buy was BioNTech: 569,574 shares worth $52.5M.
  • Deerfield Management added most to Surgery Partners in Q1 2024, an estimated $33.8M increase.
  • Deerfield Management's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $60.2M.
  • Deerfield Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $62.6M.
  • Deerfield Management's ten largest holdings make up 52% of its $5.75B portfolio in Q1 2024.
  • Deerfield Management opened 223 new positions and closed 77 in Q1 2024.
  • Deerfield Management's portfolio value rose 6.1% quarter-over-quarter to $5.75B.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.